Jahansouz Cyrus, Jahansouz Cameron, Kumer Sean C, Brayman Kenneth L
School of Medicine, University of Virginia, Charlottesville, VA 22102, USA.
J Transplant. 2011;2011:247959. doi: 10.1155/2011/247959. Epub 2011 Oct 15.
Diabetes mellitus remains one of the leading causes of morbidity and mortality worldwide. According to the Centers for Disease Control and Prevention, approximately 23.6 million people in the United States are affected. Of these individuals, 5 to 10% have been diagnosed with Type 1 diabetes mellitus (T1DM), an autoimmune disease. Although it often appears in childhood, T1DM may manifest at any age, leading to significant morbidity and decreased quality of life. Since the 1960s, the surgical treatment for diabetes mellitus has evolved to become a viable alternative to insulin administration, beginning with pancreatic transplantation. While islet cell transplantation has emerged as another potential alternative, its role in the treatment of T1DM remains to be solidified as research continues to establish it as a truly viable alternative for achieving insulin independence. In this paper, the historical evolution, procurement, current status, benefits, risks, and ongoing research of islet cell transplantation are explored.
糖尿病仍然是全球发病和死亡的主要原因之一。根据疾病控制与预防中心的数据，美国约有2360万人受到影响。在这些人中，5%至10%被诊断患有1型糖尿病（T1DM），这是一种自身免疫性疾病。虽然T1DM常出现在儿童期，但它可能在任何年龄出现，导致严重发病并降低生活质量。自20世纪60年代以来，糖尿病的外科治疗已发展成为胰岛素给药的一种可行替代方法，始于胰腺移植。虽然胰岛细胞移植已成为另一种潜在替代方法，但随着研究继续将其确立为实现胰岛素自主的真正可行替代方法，其在T1DM治疗中的作用仍有待巩固。本文探讨了胰岛细胞移植的历史演变、获取、现状、益处、风险和正在进行的研究。
